论文部分内容阅读
为了比较胞浆CD79a(CyCD79a)与包括胞浆CD22(CyCD22)、CD19、CD20和CD10等其它4种常用B系相关抗原在各种急性白血病细胞上的表达情况并寻找针对急性前体B淋巴细胞白血病(pBALL)的最敏感和特异的免疫学标志,对采用流式细胞术方法检测的221例成人和儿童急性白血病的免疫表型资料及常规细胞形态学和酶细胞化学染色资料进行了回顾性分析。另外,还对其中的45例急性早幼粒细胞白血病和13例怀疑存在AML1/ETO和CBFβ/MYH11等融合基因的急性髓细胞白血病(AML)进行了细胞遗传学和/或分子生物学检测。结果发现,对于pBALL来说,在这5种常用的B系抗原中,CyCD79a的敏感性最高,而CyCD22的特异性最好。CyCD79a在全部58例pBALL中的表达率为100%,而CyCD22在全部147例AML和15例急性前体T淋巴细胞白血病(pTALL)中则无1例表达,即在非pBALL的急性白血病中的表达率为0%。结论:联合检测CyCD79a和CyCD22是诊断pBALL的最合适的免疫学指标,能够准确地将pBALL与AML和pTALL相鉴别。
In order to compare the expression of cytoplasmic CD79a (CyCD79a) with other four commonly used B-lineage related antigens, including cytoplasmic CD22 (CyCD22), CD19, CD20 and CD10 on various acute leukemia cells and to search for acute precursor B lymphocytes The most sensitive and specific immunological markers of leukemia (pBALL) were retrospectively analyzed on immunophenotype data and routine cytomorphological and enzymatic cytochemical staining of 221 adult and childhood acute leukemias detected by flow cytometry analysis. In addition, 45 cases of acute promyelocytic leukemia and 13 cases of suspected AML1 / ETO and CBFβ / MYH11 fusion genes such as acute myeloid leukemia (AML) were cytogenetically and / or molecular biology. As a result, CyCD79a was the most potent for pBALL among the five commonly used B-line antigens, and CyCD22 was the most specific. CyCD79a was 100% in all 58 pBALLs, whereas CyCD22 was not expressed in all 147 AMLs and 15 acute precursor T-cell leukemias (pTALLs), ie, in non-pBALL acute leukemias The rate of expression was 0%. Conclusions: The combined detection of CyCD79a and CyCD22 is the most suitable immunological index for the diagnosis of pBALL, which can distinguish pBALL from AML and pTALL accurately.